-
Benzinga’s Top Pre- Market Gainers (SVA, AMCS, FTK, CGEN, PAR, NVMI, CBY)
Monday, December 28, 2009 - 9:18am | 373Sinovac Biotech Ltd. (NASDAQ: SVA) has jumped 2.40% to $6.40 in the pre-market after Sinovac Biotech announced that it has filed a clinical trial application with China's State Food and Drug Administration (SFDA) for vaccine against hand, foot, and mouth disease. In the last trading session, SVA...
-
Caliper Life Sciences Inc. (CALP) Amends Loan Pact
Thursday, December 24, 2009 - 11:55am | 118Caliper Life Sciences Inc. (NASDAQ: CALP) amended a loan agreement with a Silicon Valley Bank, according to a report by the research firm, Leerink Swann. The bank has extended the maturity date for a credit facility to April 1, 2011 from November 30, 2010. The agreement, which was originally...
-
Bio-Rad Laboratories Inc. (BIO) Denies Patent Infringement
Thursday, December 24, 2009 - 11:52am | 110Bio-Rad Laboratories Inc. (NYSE: BIO) has denied patent infringement in a suit filed by Invitrogen Corporation (NASDAQ: LIFE), according to a report by research firm Leerink Swann. The patents in question cover methods for protein production and the suit claims that Bio-Rad’s Precision Plus line...
-
Pete Najarian Is Bullish On JNJ And MDVN
Wednesday, December 23, 2009 - 8:19pm | 137Pete Najarian gave his high and low risk stock picks on CNBC's Fast Money. He likes Johnson & Johnson (NYSE: JNJ), and sees it as a low risk stock, because of its dividend yield, and good P/E ratio. The fact that Warren Buffett owns the stock is another bullish sign for him. Johnson &...
-
Pfizer Deal Enhances Compugen Share Price, (CGEN, PFE, ATHX)
Wednesday, December 23, 2009 - 1:32pm | 109Compugen Ltd’s. (NASDAQ: CGEN) deal with Pfizer Inc. (NYSE: PFE) to develop peptide products for drug candidates has been the driver for Compugen`s stock. Compugen said that the deal is expected to take a few months. Pfizer bought the rights to Athersys Inc's (NASDAQ: ATHX) stem-cell therapy to...
-
Benzinga’s Top Pre- Market Gainers (TIBX, PSDV, ACHN, FINL, SNDK, BLDP)
Wednesday, December 23, 2009 - 9:24am | 333Tibco Software Inc. (NASDAQ: TIBX) has climbed 7.62% to $9.75 after TIBX reported fourth-quarter net income of $39.2 million, or $0.23 a share from $39.9 million or $0.23 a share from the same quarter last year. While, total revenue was $195.6 million as compared to $185.5 million in the year ago...
-
Review On A’s Deal With VARI Delayed Again
Tuesday, December 22, 2009 - 2:00pm | 133The proposed takeover of peer Varian Inc (NASDAQ: VARI) by Agilent Technologies Inc (NYSE: A) has again been delayed after the European Commission (EU) extended its antitrust review by 10 working days. The EU said that the extension on the review was based on commitments offered by A. Although the...
-
CALP’s Divestiture Of Xenogen Biosciences A Positive
Tuesday, December 22, 2009 - 1:48pm | 128Analysts at Leerink Swann & Co maintain their "outperform" rating on Caliper Life Sciences Inc (NASDAQ: CALP), while reducing their estimates for the company. CALP has announced the divestiture of its Xenogen Biosciences subsidiary to Taconic Farms Inc for approximately $11 million. The...
-
NASDAQ Pre-Market Top Losers (SQNM, YONG, EZCH, PRGO, ERIC)
Thursday, December 17, 2009 - 9:55am | 152Sequenom, Inc. (NASDAQ: SQNM)(FREE stock trend analysis) declined 7.66% in the pre-market trade to $3.86, following reports that Sequenom had manipulated its Down Syndrome Data. Yongye International, Inc. (NASDAQ: YONG)(FREE stock trend analysis) declined 9.53% to $7.50 as Yongye announced a...
-
Benzinga’s Top Pre- Market Losers (C, PRGO, YONG, SQNM, EZCH, CYTX)
Thursday, December 17, 2009 - 9:48am | 284Citigroup Inc. (NYSE: C) has declined by 9.86% to $3.11 in the pre-market session. Yesterday, Citigroup Inc. prices $17 billion of common stock offering and $3.5 billion of tangible equity units. The 52-week trading range for Citigroup is $0.97 - $8.20. SO far in 2009, C declined by 48%. Yesterday...
-
Benzinga’s Biggest Losers (HLCS, CYCC, SNSS, AMED, APKT)
Wednesday, December 16, 2009 - 1:01pm | 231Helicos BioSciences Corp. (NASDAQ: HLCS)(FREE stock trend analysis) has plunged 30.51% to $0.952 on 5.31 million shares after Helicos BioSciences announced that it has priced a registered direct offering of 6.4 million units, at a price of $1.00 per unit. So far this year, HLCS is up over 144%....
-
New Additions To The Nasdaq 100 Index
Monday, December 14, 2009 - 1:56am | 110The following companies will be added to the Nasdaq 100 Index, meaning a few new members for the PowerShares QQQ ETF (Nasdaq: QQQQ). Software maker BMC Software (Nasdaq: BMC), toymaker Mattel (Nasdaq: MAT), generic drug producer Mylan (Nasdaq: MYL), Dutch biotech firm Qiagen (Nasdaq: QGEN),...
-
Setback for Endo Pharma - Analyst Blog
Friday, December 11, 2009 - 11:46am | 446Endo Pharmaceuticals (ENDP) hit a roadblock related to the approval of Aveed. Recently, the company received a complete response letter (CRL) from the US Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for its injectable testosterone product Aveed for men diagnosed with...
-
Benzinga’s Top Upgrades (COO, ATK, MMM, UNT, LQDT, SQNM)
Wednesday, December 9, 2009 - 10:58am | 231The Cooper Companies, Inc. (NYSE: COO) was today upgraded by Wells Fargo to Outperform from Market Perform and raised the price target range to $41-$43 from $28-$30. COO is now trading at $37.35, 10.11% up. So far in 2009, COO has gained over 129%. Alliant Techsystems Inc. (NYSE: ATK) fell 0.56% to...
-
AstraZeneca: More Good News - Analyst Blog
Monday, December 7, 2009 - 7:00pm | 383Good news for AstraZeneca (AZN) once again! The company received US Food and Drug Administration (FDA) approval for Seroquel XR (quetiapine fumarate) as an add-on treatment to antidepressants in adults with Major Depressive Disorder (MDD). Seroquel XR is an extended-release version of the company’...